Physiologically based pharmacokinetic modeling of nanoparticles.

Rapid expansion of nanoparticle research demands new technologies that will enable better interpretation of experimental data and assistance in the rational design of future nanoparticles. The use of physiologically based pharmacokinetic (PBPK) models may serve as powerful tools to meet these needs. PBPK models have been successfully applied for the study of the absorption, distribution, metabolism, and excretion (ADME) of small molecules, such as drugs. Preliminary application of PBPK models to nanoparticles illustrated their potential usefulness for nanoparticle ADME research. However, due to the differences between nanoparticles and small molecules, modifications are needed to build appropriate PBPK models for nanoparticles. This review is divided into two sections, with the first discussing nanoparticle ADME research, emphasizing the interaction of nanoparticles with living systems, including transportation kinetics across biobarriers. In the second section, the basic principles of PBPK model development are introduced, and research pertaining to PBPK models of nanoparticles is reviewed. Factors that need to be considered for developing PBPK models for nanoparticles are also discussed. Finally, perspective applications of nanoparticle PBPK models are summarized.

[1]  R. Ings,et al.  Interspecies scaling and comparisons in drug development and toxicokinetics. , 1990, Xenobiotica; the fate of foreign compounds in biological systems.

[2]  J. Kreuter,et al.  Distribution and elimination of poly(methyl-2-14C-methacrylate) nanoparticle radioactivity after injection in rats and mice. , 1979, Journal of pharmaceutical sciences.

[3]  Meng Wang,et al.  Particokinetics and extrapulmonary translocation of intratracheally instilled ferric oxide nanoparticles in rats and the potential health risk assessment. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[4]  Kostas Kostarelos,et al.  Tumor targeting of functionalized quantum dot-liposome hybrids by intravenous administration. , 2009, Molecular pharmaceutics.

[5]  M. Prato,et al.  Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[6]  H. Alpár,et al.  Potential use of nanoparticles for transcutaneous vaccine delivery: effect of particle size and charge. , 2004, International journal of pharmaceutics.

[7]  H. Swai,et al.  In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. , 2010, Nanomedicine : nanotechnology, biology, and medicine.

[8]  Yves-Jacques Schneider,et al.  Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[9]  Ivan Nestorov,et al.  Whole-body physiologically based pharmacokinetic models , 2007, Expert opinion on drug metabolism & toxicology.

[10]  Ming-Hsien Tsai,et al.  Persistent Tissue Kinetics and Redistribution of Nanoparticles, Quantum Dot 705, in Mice: ICP-MS Quantitative Assessment , 2007, Environmental health perspectives.

[11]  R. Jain Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[12]  M. de la Fuente,et al.  Chitosan nanoparticles for drug delivery to the eye , 2009, Expert opinion on drug delivery.

[13]  S. Batra,et al.  A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs. , 2008, International immunopharmacology.

[14]  Saber M Hussain,et al.  Modeling the In Vivo Case with In Vitro Nanotoxicity Data , 2008, International journal of toxicology.

[15]  J. Hanes,et al.  Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. , 2009, Advanced drug delivery reviews.

[16]  H. Ando,et al.  Circulation time and body distribution of protein A-coated amino modified polystyrene nanoparticles in mice , 1995 .

[17]  Abderrahim Nemmar,et al.  Development of a physiologically based kinetic model for 99m-Technetium-labelled carbon nanoparticles inhaled by humans , 2009, Inhalation toxicology.

[18]  Ande Bao,et al.  Dynamic Imaging of Functionalized Multi‐Walled Carbon Nanotube Systemic Circulation and Urinary Excretion , 2008 .

[19]  M. Qiao,et al.  Lectin-conjugated PLGA nanoparticles loaded with thymopentin: ex vivo bioadhesion and in vivo biodistribution. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[20]  Robert Sturm,et al.  A computer model for the clearance of insoluble particles from the tracheobronchial tree of the human lung , 2007, Comput. Biol. Medicine.

[21]  Nicholas A Peppas,et al.  Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.

[22]  E. Nakamura,et al.  In vivo biological behavior of a water-miscible fullerene: 14C labeling, absorption, distribution, excretion and acute toxicity. , 1995, Chemistry & biology.

[23]  D. Corry,et al.  The migration of bronchoalveolar macrophages into hilar lymph nodes. , 1984, The American journal of pathology.

[24]  J. Nah,et al.  SPION-loaded chitosan-linoleic acid nanoparticles to target hepatocytes. , 2009, International journal of pharmaceutics.

[25]  H. Dai,et al.  In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. , 2020, Nature nanotechnology.

[26]  V. Lenaerts,et al.  In vivo uptake of polyisobutyl cyanoacrylate nanoparticles by rat liver Kupffer, endothelial, and parenchymal cells. , 1984, Journal of pharmaceutical sciences.

[27]  R. Sharma,et al.  Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[28]  Ralph Weissleder,et al.  Binding affinity and kinetic analysis of targeted small molecule-modified nanoparticles. , 2010, Bioconjugate chemistry.

[29]  Sai T Reddy,et al.  Exploiting lymphatic transport and complement activation in nanoparticle vaccines , 2007, Nature Biotechnology.

[30]  Dwight Romanovicz,et al.  Biodistribution and long-term fate of silver nanoparticles functionalized with bovine serum albumin in rats. , 2010, Metallomics : integrated biometal science.

[31]  James A J Fitzpatrick,et al.  Sentinel lymph node imaging using quantum dots in mouse tumor models. , 2007, Bioconjugate chemistry.

[32]  Si-Shen Feng,et al.  Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. , 2005, Biomaterials.

[33]  Sandra L. Schmid,et al.  Regulated portals of entry into the cell , 2003, Nature.

[34]  Kostas Kostarelos,et al.  The emergence of nanomedicine: a field in the making. , 2006, Nanomedicine.

[35]  Gert Storm,et al.  Sheddable Coatings for Long-Circulating Nanoparticles , 2007, Pharmaceutical Research.

[36]  Chung-Min Liao,et al.  Model-based assessment for human inhalation exposure risk to airborne nano/fine titanium dioxide particles. , 2008, The Science of the total environment.

[37]  Wei Yang,et al.  Inhaled nanoparticles--a current review. , 2008, International journal of pharmaceutics.

[38]  M. Dobrovolskaia,et al.  Immunological properties of engineered nanomaterials , 2007, Nature Nanotechnology.

[39]  R K Jain,et al.  Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. , 1995, Cancer research.

[40]  Hugh A. Barton,et al.  Database for Physiologically Based Pharmacokinetic (PBPK) Modeling: Physiological Data for Healthy and Health-Impaired Elderly , 2009, Journal of toxicology and environmental health. Part B, Critical reviews.

[41]  H. Reynolds,et al.  Macrophages and polymorphonuclear neutrophils in lung defense and injury. , 1990, The American review of respiratory disease.

[42]  Agnes G Oomen,et al.  What do we (need to) know about the kinetic properties of nanoparticles in the body? , 2007, Regulatory toxicology and pharmacology : RTP.

[43]  Chao‐Nan Xu,et al.  Giant negative thermal expansion in magnetic nanocrystals. , 2008, Nature nanotechnology.

[44]  R K Jain,et al.  Determinants of tumor blood flow: a review. , 1988, Cancer research.

[45]  W. D. de Jong,et al.  The kinetics of the tissue distribution of silver nanoparticles of different sizes. , 2010, Biomaterials.

[46]  J. Cheon,et al.  Pharmacokinetic properties and tissue storage of FITC conjugated SA-MnMEIO nanoparticles in mice , 2009 .

[47]  M. Ferrari,et al.  Quantitative mechanics of endothelial phagocytosis of silicon microparticles , 2009, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[48]  Lang Tran,et al.  Nanoparticles, human health hazard and regulation , 2010, Journal of The Royal Society Interface.

[49]  Akiyoshi Hoshino,et al.  Applications of T-lymphoma labeled with fluorescent quantum dots to cell tracing markers in mouse body. , 2004, Biochemical and biophysical research communications.

[50]  Hugues Dolgos,et al.  Physiologically based pharmacokinetic (PBPK) modeling and simulation: applications in lead optimization. , 2009, Current opinion in drug discovery & development.

[51]  J. Bacri,et al.  Interaction of Anionic Superparamagnetic Nanoparticles with Cells: Kinetic Analyses of Membrane Adsorption and Subsequent Internalization , 2002 .

[52]  W. Deen What determines glomerular capillary permeability? , 2004, The Journal of clinical investigation.

[53]  Elaina M Kenyon,et al.  A physiologically based pharmacokinetic model for intravenous and ingested dimethylarsinic acid in mice. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[54]  Wolfgang Kreyling,et al.  Toxicological hazards of inhaled nanoparticles--potential implications for drug delivery. , 2004, Journal of nanoscience and nanotechnology.

[55]  V. Fuster,et al.  Macrophage-specific lipid-based nanoparticles improve cardiac magnetic resonance detection and characterization of human atherosclerosis. , 2009, JACC. Cardiovascular imaging.

[56]  Robert Gelein,et al.  EXTRAPULMONARY TRANSLOCATION OF ULTRAFINE CARBON PARTICLES FOLLOWING WHOLE-BODY INHALATION EXPOSURE OF RATS , 2002, Journal of toxicology and environmental health. Part A.

[57]  Jim E Riviere,et al.  Pharmacokinetics of nanomaterials: an overview of carbon nanotubes, fullerenes and quantum dots. , 2009, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[58]  J. Finkelstein,et al.  Translocation of Inhaled Ultrafine Manganese Oxide Particles to the Central Nervous System , 2006, Environmental health perspectives.

[59]  N Hussain,et al.  Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. , 2001, Advanced drug delivery reviews.

[60]  Håkan Wallin,et al.  Kupffer cells are central in the removal of nanoparticles from the organism , 2007, Particle and Fibre Toxicology.

[61]  C. Liao,et al.  Dynamical coupling of PBPK/PD and AUC-based toxicity models for arsenic in tilapia Oreochromis mossambicus from blackfoot disease area in Taiwan. , 2005, Environmental pollution.

[62]  Malcolm Rowland,et al.  Lumping of Whole-Body Physiologically Based Pharmacokinetic Models , 1998, Journal of Pharmacokinetics and Biopharmaceutics.

[63]  Yuichi Sugiyama,et al.  In vitro andin vivo evaluation of the tissue-to-blood partition coefficient for physiological pharmacokinetic models , 1982, Journal of Pharmacokinetics and Biopharmaceutics.

[64]  Jim E Riviere,et al.  Comparison of quantum dot biodistribution with a blood-flow-limited physiologically based pharmacokinetic model. , 2009, Nano letters.

[65]  W. Saltzman,et al.  The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. , 2009, Biomaterials.

[66]  Frank Caruso,et al.  Nanoengineering of Particle Surfaces , 2001 .

[67]  Mina Choi,et al.  The impact of size on tissue distribution and elimination by single intravenous injection of silica nanoparticles. , 2009, Toxicology letters.

[68]  Jayanth Panyam,et al.  Dynamics of Endocytosis and Exocytosis of Poly(D,L-Lactide-co-Glycolide) Nanoparticles in Vascular Smooth Muscle Cells , 2003, Pharmaceutical Research.

[69]  C Timchalk,et al.  A Physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model for the organophosphate insecticide chlorpyrifos in rats and humans. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[70]  S. Moghimi Modulation of lymphatic distribution of subcutaneously injected poloxamer 407‐coated nanospheres: the effect of the ethylene oxide chain configuration , 2003, FEBS letters.

[71]  Ming-Hsien Tsai,et al.  Computational and ultrastructural toxicology of a nanoparticle, Quantum Dot 705, in mice. , 2008, Environmental science & technology.

[72]  K. Avgoustakis,et al.  Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. , 2001, International journal of pharmaceutics.

[73]  E. Kuempel,et al.  Development of a bio-mathematical model in rats to describe clearance, retention and translocation of inhaled nano particles throughout the body , 2009 .

[74]  R K Jain,et al.  Physiologically based pharmacokinetic modeling: principles and applications. , 1983, Journal of pharmaceutical sciences.

[75]  M. Bawendi,et al.  Renal clearance of quantum dots , 2007, Nature Biotechnology.

[76]  Kazunori Kataoka,et al.  PEGylated Nanoparticles for Biological and Pharmaceutical Applications , 2003 .

[77]  R M Albrecht,et al.  Gastrointestinal persorption and tissue distribution of differently sized colloidal gold nanoparticles. , 2001, Journal of pharmaceutical sciences.

[78]  Warren C W Chan,et al.  Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. , 2007, Nano letters.

[79]  Anderson,et al.  Biodegradation and biocompatibility of PLA and PLGA microspheres. , 1997, Advanced drug delivery reviews.

[80]  Scott E McNeil,et al.  Translational considerations for cancer nanomedicine. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[81]  Indrajit Roy,et al.  In vivo biodistribution and clearance studies using multimodal organically modified silica nanoparticles. , 2010, ACS nano.

[82]  M. Hashida,et al.  Biliary excretion of polystyrene microspheres depends on the type of receptor-mediated uptake in rat liver. , 2001, Biochimica et biophysica acta.

[83]  E. Debefve,et al.  Effect of nanoparticle size on the extravasation and the photothrombic activity of meso(p-tetracarboxyphenyl)porphyrin. , 2006, Journal of photochemistry and photobiology. B, Biology.

[84]  T. Yanagishita,et al.  Fabrication of monodisperse polymer nanoparticles by membrane emulsification using ordered anodic porous alumina. , 2010, Langmuir : the ACS journal of surfaces and colloids.

[85]  Petra Krystek,et al.  Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. , 2008, Biomaterials.

[86]  Ivan Nestorov,et al.  Whole Body Pharmacokinetic Models , 2003, Clinical pharmacokinetics.

[87]  R. Shukla,et al.  Biocompatibility of gold nanoparticles and their endocytotic fate inside the cellular compartment: a microscopic overview. , 2005, Langmuir : the ACS journal of surfaces and colloids.

[88]  Stephen T Holgate,et al.  Exposure, uptake, distribution and toxicity of nanomaterials in humans. , 2010, Journal of biomedical nanotechnology.

[89]  L. Brannon-Peppas,et al.  Nanoparticle and targeted systems for cancer therapy. , 2004, Advanced drug delivery reviews.

[90]  K. Kwon Development of physiological pharmacokinetic model , 1987 .

[91]  Katharina Landfester,et al.  Interaction of nanoparticles with cells. , 2009, Biomacromolecules.

[92]  Han-Joo Lee,et al.  Antibacterial effect of nanosized silver colloidal solution on textile fabrics , 2003 .

[93]  G. Grass,et al.  Physiologically-based pharmacokinetic simulation modelling. , 2002, Advanced drug delivery reviews.

[94]  M. Botelho,et al.  Lymphatic Uptake of Pulmonary Delivered Radiolabelled Solid Lipid Nanoparticles , 2002, Journal of drug targeting.

[95]  M F Hoylaerts,et al.  Passage of intratracheally instilled ultrafine particles from the lung into the systemic circulation in hamster. , 2001, American journal of respiratory and critical care medicine.

[96]  P. Couvreur,et al.  Hepatic tissue distribution of doxorubicin-loaded nanoparticles after i.v. administration in reticulosarcoma M 5076 metastasis-bearing mice , 2008, Cancer Chemotherapy and Pharmacology.

[97]  A. Webster,et al.  Deposition and clearance of monodisperse aerosols in the calf lung: effects of particle size and a mucolytic agent (bromhexine) , 1987, Canadian journal of veterinary research = Revue canadienne de recherche veterinaire.

[98]  D. Pouliquen,et al.  Biodegradation of magnetite dextran nanoparticles in the rat. A histologic and biophysical study. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[99]  M Milanese,et al.  Description and simulation of a physiological pharmacokinetic model for the metabolism and enterohepatic circulation of bile acids in man. Cholic acid in healthy man. , 1983, The Journal of clinical investigation.

[100]  G. Oberdörster,et al.  Nanotoxicology: An Emerging Discipline Evolving from Studies of Ultrafine Particles , 2005, Environmental health perspectives.

[101]  P. Couvreur,et al.  Lymphatic Targeting of Polymeric Nanoparticles After Intraperitoneal Administration in Rats , 1992, Pharmaceutical Research.

[102]  M. Okino,et al.  Parameters for Carbamate Pesticide QSAR and PBPK/PD Models for Human Risk Assessment. , 2008, Reviews of environmental contamination and toxicology.

[103]  S. Schürch,et al.  Interaction of fine particles and nanoparticles with red blood cells visualized with advanced microscopic techniques. , 2006, Environmental science & technology.

[104]  Mauro Ferrari,et al.  The Transport of Nanoparticles in Blood Vessels: The Effect of Vessel Permeability and Blood Rheology , 2008, Annals of Biomedical Engineering.

[105]  Bobbi K Lewis,et al.  A model of lysosomal metabolism of dextran coated superparamagnetic iron oxide (SPIO) nanoparticles: implications for cellular magnetic resonance imaging , 2005, NMR in biomedicine.

[106]  P. Couvreur,et al.  Splenic Trapping of Nanoparticles: Complementary Approaches for In Situ Studies , 1997, Pharmaceutical Research.

[107]  Sulin Zhang,et al.  Effects of particle size and ligand density on the kinetics of receptor-mediated endocytosis of nanoparticles , 2010 .

[108]  Nigel J Walker,et al.  Migration of intradermally injected quantum dots to sentinel organs in mice. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[109]  S. Nie,et al.  In vivo cancer targeting and imaging with semiconductor quantum dots , 2004, Nature Biotechnology.

[110]  Parag Aggarwal,et al.  Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. , 2009, Advanced drug delivery reviews.

[111]  F. Hindré,et al.  Comparative biodistribution of thin‐coated iron oxide nanoparticles TCION: Effect of different bisphosphonate coatings , 2001 .

[112]  Z. Tang,et al.  Mechanism of Strong Luminescence Photoactivation of Citrate-Stabilized Water-Soluble Nanoparticles with CdSe Cores , 2004 .

[113]  P. Choyke,et al.  Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. , 2008, Nanomedicine.

[114]  L Morawska,et al.  Environmental tobacco smoke deposition in the human respiratory tract: differences between experimental and theoretical approaches. , 2001, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[115]  P. Couvreur,et al.  Nanoparticles in cancer therapy and diagnosis. , 2002, Advanced drug delivery reviews.

[116]  J. Grothaus,et al.  Tissue distribution of 20 nm, 100 nm and 1000 nm fluorescent polystyrene latex nanospheres following acute systemic or acute and repeat airway exposure in the rat. , 2009, Toxicology.

[117]  M. Wirth,et al.  Binding and Uptake of Wheat Germ Agglutinin-Grafted PLGA-Nanospheres by Caco-2 Monolayers , 2004, Pharmaceutical Research.

[118]  Yolonda L Colson,et al.  Expansile nanoparticles: synthesis, characterization, and in vivo efficacy of an acid-responsive polymeric drug delivery system. , 2009, Journal of the American Chemical Society.

[119]  Alexander Star,et al.  Biodegradation of single-walled carbon nanotubes through enzymatic catalysis. , 2008, Nano letters.

[120]  A. Maruyama,et al.  Receptor-mediated cell modulator delivery to hepatocyte using nanoparticles coated with carbohydrate-carrying polymers. , 2001, Biomaterials.

[121]  L. C. Wyman,et al.  BLOOD FLOW RATES OF INTACT AND REGENERATED RAT ADRENALS DURING STRESS. , 1964, American Journal of Physiology.

[122]  K. Avgoustakis,et al.  Effect of copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of PLGA-mPEG nanoparticles. , 2003, International journal of pharmaceutics.

[123]  Brahim Lounis,et al.  Cathepsin L digestion of nanobioconjugates upon endocytosis. , 2009, ACS nano.

[124]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[125]  W. Mark Saltzman,et al.  Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA , 2009, Nature materials.

[126]  Walter Schmitt,et al.  Development of a Physiology-Based Whole-Body Population Model for Assessing the Influence of Individual Variability on the Pharmacokinetics of Drugs , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[127]  Y. Nishioka,et al.  Lymphatic targeting with nanoparticulate system. , 2001, Advanced drug delivery reviews.

[128]  P Couvreur,et al.  In vitro evaluation of nanoparticles spleen capture. , 1999, Life sciences.

[129]  Baorui Liu,et al.  Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.